reason report
cautiou cv program competit risk initi
bottom line initi coverag arrowhead
pharmaceut inc under-perform rate
price target pt safeti profil regulatori path lead asset aro-
antitrypsin defici remain uncertain competitor
data mp existenti threat program non-dilut
financ potenti royalti op partnership
fulli valu current level develop cardiovascular
lipid pipelin behind pharma competitor like
launch lower-pr agent broad label robust data sizeabl
sale forc reach market tough catalyst
path current valuat bake substanti technolog valu despit
patient-year exposur trim platform see next
month far challeng past two year
face sky-high expect face increasingli clear competit
regulatori safeti technolog risk aro-aat hard
pill swallow arwr lead asset aro-aat lead among
rnai compani competitor pathway approv dataset
on-going sequoia studi remain uncertain small molecul
corrector data form potenti existenti threat program
corrector may aro-aat could potenti
aggrav lung diseas antitrypsin defici aatd patient
receiv drug treat liver diseas small molecul corrector
develop offer pathway materi improv liver
lung diseas conveni pill updat first
sever corrector expect repres major risk
catalyst street aro-aat estim
cant save day valuat hepat viru
hbv program along target partner offer non-
dilut mileston royalti fulli valu
current level
cv franchis earli behind competitorsth remain
asset arwr pipelin consist cardiovascular cv lipid
franchis made asset earli human trial target
genet valid face well-fund competit anti-
sens oligonucleotid partner establish pharma player
suggest orphan price necessari captur
valu asset may realiz launch drug
lower-pr competitor broad label robust dataset
sizeabl sale forc outsid arwr core compet
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
substanti premium bake share struggl
reach current valuat base fundament valu
arwr clinic program pipelin see substanti
premium bake level partner transact key
pipelin asset strong data competitor
cardiometabol program could flatten premium
rate share under-perform lead asset aro-aat ahead
oligotherapeut compani competitor pathway approv dataset
on-going sequoia studi remain uncertain small molecul corrector data
potenti existenti threat program partner hbv program sourc
non-dilut financ potenti royalti cash flow fulli valu current
level remain asset arwr pipelin consist cardiovascular lipid franchis
made asset earli human trial number unproven non-liv program
remain exceedingli earli target genet valid face well-fund
competit anti-sens oligonucleotid partner establish pharma player
suggest orphan price necessari captur valu asset
may realiz launch drug lower-pr competitor broad
label robust dataset sizeabl sale forc outsid arwr core compet current
valuat share bake substanti technolog valu base assumpt
trim platform safe effect extrapol dataset present rnai pioneer
may prove incorrect given patient-year exposur
trim platform date
price target base discount cash flow methodolog
project potenti sale royalti aro-aat
risk-adjust basi explicitli model expens forecast result cash
flow assign termin growth rate discount rate consist
clinical-stag pre-revenu compani coverag univers addit
includ arwr net cash balanc valuat
major risk view outlook valuat share activ includ
acquisit compani substanti premium stand-alon valu addit risk
includ major chang reimburs coverag rare diseas agent unexpect
safeti signal clinic develop candid trim platform forecast
subject unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share rnai-bas therapi develop compani
partner convers forecast may prove conserv competit agent
compet rnai agent vrtx oral candid defici fail
progress clinic trial unprofit like remain time greater-
than-expect oper expens cash burn could lead dilut equiti issuanc
frequent less attract valuat project convers greater-than-expect non-
dilut partnership capit inflow oper expens project would present
upsid risk view
arrowhead pharmaceut background pipelin
arrowhead drug develop driven proprietari rnai platform
five drug candid clinic develop util trim platform
target rnai molecul platform direct conjug ligand deliveri liver
arwr design philosophi select incorpor backbon modif stabil
chemistri need achiev desir level target knockdown durat
effect util proprietari linker branch point stabil chemistri proprietari
algorithm select rule design rna trigger sequenc exhibit detail
descript trim platform ligand chemistri yet disclos presum
trade secret remain closely-guard competit reason rnai
mechan action ident oligonucleotid drug develop mp
op differenti vs platform remain demonstr clinic
liver-direct rnai medicin lead clinic pipelin aro-aat treatment
antitrypsin liver diseas phase ii/iii develop
hypertriglyceridemia phase dyslipidemia phase
hepat viru phase ii cardiovascular diseas cvd phase form
core arwr portfolio exhibit asset util asialoglycoprotein
receptor asgpr -target ligand deliv rnai liver demonstr
robust knockdown gene express liver proof mechan principl
see deliveri rnai liver trim substanti de-risk
pipelin asset aim first-in-class provid differenti safety/dos
aro-aat track first rnai therapeut treatment aatd-rel liver
diseas expect first rnai treatment incorpor
potenti cur therapi hbv afford compound first mover advantag
competitor mp though length commerci relev
lead vari indic arwr cardiometabol franchis lag behind ions/acka
program vari degre pivot phase trial akcea-apo -lrx expect
initi complet phase ii studi earli
data phase iib trial akcea-apociii-lrx expect present
arwr cardiometabol asset phase trial expect initi
phase ii trial howev arwr rnai mechan potenti
differenti ionss anti-sens oligonucleotid aso depth knockdown
durabl respons compound like enter pivot studi once-per-
month dose regimen pharmacokinetics/pharmacodynam pk/pd trim oligo
support dose interv month count
conveni benefit first market competitor nag concern platelet
safeti continu dog percept platform due issu seen earlier
gener technolog creat opportun trim product
partnership provid meaning mileston potenti
royalti announc janssen partnership octob includ
cash payment equiti invest total
deal includ potenti hbv program mileston payment addit
potenti mileston three undisclos novel target tier royalti mid-
teen establish partnership aro-lpa amg-
program respons clinic develop commerci
drug elig option payment develop
regulatori sale mileston low double-digit royalti sale
chose exercis option licens juli
mileston royalti payment agreement
pursu target outsid liver though proof concept limit
anim model trim platform could theoret address diseas caus
overexpress protein compani number conjug ligand
develop aim target tissu outsid liver util integrin
receptor mimet ligand target renal cell carcinoma aro-enac conjug
integrin ligand treatment cystic fibrosi detail ligand
yet disclos though initi preclin vivo data present arwr
 day suggest compound achiev tissu specif demonstr
knockdown mous xenograft model sheep treat inhal
aro-enac display increas mucociliari clearanc provid initi proof-of-concept
model deliveri anim model howev drug candid potenti
product-market fit incongru exhibit view hamper potenti clinic
profil cystic fibrosi cf caus toxic gain-of-funct enac
may common driver renal cell carcinoma rcc rnai checker histori
cancer high propens mutation/inst genet sequenc make
svb leerink research singl patholog protein caus multipl gene mutat proport
normal protein function must restor induc clinic improv ert enzym replac therapi
current market valuat challeng us reach base fundament
analysi share current trade impli market cap far
dcf-base valuat explicitli model probability-weight revenu
aro-aat program royalti mileston jnj-
partnership dcf-base valuat believ
substanti unsupport platform valu premium bake share current
market valuat line closest rnai antisens oligonucleotid aso
competitor base earli stage clinic develop limit number drug
clear pathway commerci exhibit view also
underappreci potenti clinic commerci challeng face
much arwr fundament valuat tie liver diseas
opportun meaning patient identif competit challeng
number competitor develop compet aatd liver diseas therapi
mp op announc compet rnai program
specif address liver diseas op develop gene edit approach
yet patient op advanc multipl small-molecul corrector
could potenti treat aatd-associ lung liver diseas rnai
gene edit approach treat liver diseas could potenti exacerb
lung diseas small molecul corrector could potenti address diseas
organ conveni oral pill success clinic believ
vrtx small molecul corrector could materi superior therapi arwr
rnai-bas approach diseas loom threat commerci
success aro-aat
larg primari secondari prevent indic cardiometabol drug
competit limit price opportun larg pharmaceut
competitor novarti develop oligonucleotide-bas drug
like develop larg primari secondari prevent market
specif regard precis target indic develop pathway
unknown point believ degre overlap
interchang agent preliminari data indic knockdown
apoiii apo lower ldl-cholesterol knockdown
reduc triglycerid price larg indic expect
similar approv antibodi per year potenti
much lower knockdown agent inclisiran nv like use
lower price lever negoti captur share success develop
drug presum larg market share competit environ
metabol diseas like short orphan price window
advanc multipl wholly-own asset phase
studi could potenti see use orphan mass-market primari care
indic first develop asset orphan indic
syndrom fc famili partial lipodystrophi fpl provid earli clinic
proof concept expedit path approv drug orphan indic
often abl secur high price point
limit price power due compet agent akcea-apociii-lrx
akca/novarti akca/pf may approv
larg cardiometabol indic shortli approv
orphan indic expect price fall line broader
indic patient orphan diseas fc hofh like fall
broad label larger indic drive price oligo
compani struggl retain share especi price-sensit environ like
approv broad cardiometabol indic
requir larg cardiovascular outcom studi pivot fourier trial
repatha patient establish cardiovascular diseas cvd
elev ldl-c requir patient trial reduce-it trial
vascepa amrn op enrol patient util endpoint
evalu cv outcom approv patient rest triglycerid mg/dl
see arwr partnership cvd associ elev
apo realist develop strategi given cost associ cv
outcom studi though drug remain year behind develop
manag commun inbound interest
focus partner asset exist pipelin muddl
develop pathway cardiometabol asset larg indic
exhibit rnai/aso compar
compani report factset market cap calcul market open
current level share adequ contempl competit
cardiometabol environ primari secondari prevent bull thesi
part base larg market opportun primari secondari prevent
note field increasingli crowd numer competitor differ
antibodi mp /regn op lipid-regul agent vascepa amrn
well-character knockdown target investig apo
potenti overlap effect triglycerid cholesterol ldl-c
produc competit market rel undifferenti treatment option exhibit
label restrict treatment small segment patient specif risk factor
like compani lack infrastructur pursu cvot studi requir
broader label payor like requir step-through lowest cost treatment option
vascepa inclisiran etc arwr late-to-market agent approv
consid sever year behind develop unfavor market
dynam well entrench complet pivot studi
cardiometabol pipelin make clinic trial enrol challeng
competitor data cardiometabol diseas neg skew risk/reward
rel pauciti major clinic catalyst phase
data long-term follow data tripl
combin studi hbv event year trial initi rather
data exhibit potenti upsid readout overshadow threat
later-stag competitor data exhibit view visibl potenti neg
catalyst clinic data vrtx program promis data
studi patient aatd-rel lung diseas would suggest util lung
liver manifest aatd present superior product-market fit safety/efficaci
profil vs rnai approach aro-aat phase ii readout akcea-
akcea-apociii-lrx also expect highlight
investor long time-frame high cost cv outcom studi far behind
arwr cardiometabol program vs competitor
targetcompanydrugindicationstag ph on-going hv completeions/akcea hofh hypertriglyceridemia type diabet mellitu nafldph on-going estim complet mab hofh hypercholesterolemiabla file apo ph initi nv akcea-apo -lrxcvd apo ph on-going estim primari complet hypertriglyceridemia tg mg/dl ph on-going hv completeions/akceawaylivrafc fplapprov eu fc ph fpl ions/akceaakcea-apociii-lrxhypertriglyceridemia tg mg/dl ph ldl-c mg/dl tg mg/dl hofh hefhnda submiss eu submiss tg arrowhead inc
stock ticker symbol later impact companies/stock drug brand chemic name indicationtyp eventev trial detailsexpectedtimingsvb leerink view expect outcom antitrypsinphas ii data announcementpotenti interim updat sequoia open label famili hypercholesterolemiaphas data presentationphas data present dyslipidemia famili hypercholesterolemiaphas ii trial chylomicronemia syndrom phase data presentationphas data present patient hypertriglyceridemia chylomicronemia syndrom phase ii trial arwramgnamg elev lp phase ii trial data presentationinterim readout cell carcinomaoth eventphas trial initi arwraro-enaccyst fibrosisoth eventphas trial initi arwraro-hsdnashoth eventphas trial initi catalyst tracker stock ticker symbol later impact companies/stock drug brand chemic name indicationtyp eventev trial detailsexpectedtimingsvb leerink view expect outcom data present report clinic data peopl two mutat eventcontinu advanc eventdos first patient phase cardiometabol catalyst trackerstock ticker symbol later impact companies/stock drug brand chemic name indicationtyp eventev trial detailsexpectedtimingsvb leerink view expect outcom amrnarwrvascepaelev tg/cv indicationoth eventongo launch patient tg non-alcohol fatti liver diseasephas ii data announcementphas ii top line data nvsarwrakcea-apo -lrxcardiovascular diseas cvd phase trial initiationfirst patient dose cardiovascular outcom ionsarwr akcea-apoc-lrxhypertriglyceridemiaphas ii data announcementphas ii top line data mdcoarwrinclisirancardiovascular diseas cvd fda approvalanticip approv arrowhead inc
antitrypsin defici genet disord manifest liver lung
diseas aatd caus inherit mutat serpina gene encod
antitrypsin protein proteas inhibitor modul activ neutrophil
elastas degrad enzym secret immun cell inflamm insuffici
express protein caus lung vulner inflammatori injuri
uninhibit neutrophil proteas separ mechan accumul misfold
protein liver caus liver diseas subset patient exhibit
estim us patient risk aatd liver diseas sever mutat
serpina lead aatd patient homozyg pi allel
sever form aatd associ high risk liver diseas pi zz aatd
frequent genet caus liver diseas pediatr patient second
common caus liver transplant children migliazza et al pediatr surg
estim us patient pi zz genotyp individu
develop liver diseas lifetim nord rare diseas databas though aatd liver
diseas highli variabl present age onset sever teckman et al
pediatr gastroenterol nutr pi allel highest preval europ
individu northern western european descent us kohnlein et al ther adv
respir preval gener popul western europ approxim
newborn us inherit pi zz genotyp fregones et al
misfold pi protein caus liver lung diseas pi allel
serpina produc protein propens misfold aggreg inclus
bodi becom trap liver greulich al ther adv respir
manifest cirrhosi hepatocellular carcinoma hepat lead liver failur de
serr fj environment health perspect patient homozyg pi also
high risk lung complic sinc small fraction produc protein
escap liver serum level typic normal exhibit
form risk liver diseas pi allel produc protein
degrad prematur pi ss patient moder reduc serum protein
low risk develop emphysema risk liver diseas patient
complet null protein express also risk liver diseas though
high risk develop lung complic
exhibit clinic manifest aatd
exhibit serum risk emphysema liver diseas genotyp
aro-aat good scientif rational treatment aatd liver diseas aro-aat
target conserv region mrna knock normal mutant
version gene sinc aat-rel liver diseas caus accumul misfold
protein liver rnai knockdown solid scientif rational amelior
root caus liver diseas pi zz patient well offer attract product-
market fit oligo therapi see exhibit given aatd liver diseas toxic gain
function diseas requir high level protein modif drive clinic benefit
preclin experi pi mice show aro-att prevent build-up toxic protein
liver exhibit experi util earlier gener arc-aat oligo
demonstr rnai mediat rapid deplet solubl monomer protein
significantli decreas polymer protein week treatment exhibit
evid rnai-medi knockdown may abl revers build-up toxic
protein inclus bodi improv liver function time
exhibit aro- prevent hepat accumul piz mice
exhibit aro- reduc monom polym piz mice
though knockdown protein could exacerb lung diseas knockdown
shift patient pi zz phenotyp null-lik phenotyp
pi zz genotyp patient retain approxim protein express
serum treatment aro- reduc serum even exhibit
patient complet null express exhibit sever lung phenotyp
aatd patient fregones et la respir suggest deplet serum
could put patient higher risk lung complic serum normal fall
mg/dl healthi individu teckman jh copd serum
concentr least mg/dl thought protect lung diseas
emphysema stoller et al lancet phase studi healthi volunt
knockdown achiev sustain serum concentr
approxim mg/dl exhibit well protect level spoke
medacorp kol believ exacerb lung diseas due knockdown
concern close monitor clinic trial note lung diseas
unlik occur without insult injuri lung aatd lung diseas caus
smoke non-smok typic present lung diseas late life
data suggest protein augment iv infus slow declin
forc expiratori volum fev patient baselin moderate-to-sever obstruct
bergin et al immunol ther would option avail patient
experi exacerb lung diseas aro-aat treatment though
cost effici clinic signific augment controversi within
potenti pivot placebo-control phase ii/iii sequoia trial initi
though path approv aatd remain opaqu sequoia divid two
part part dose select studi evalu reduct insolubl hepat
protein serum protein day treatment part evalu efficaci
select dose liver biopsi exhibit aro-aat receiv fast-track
design expedit regulatori process though unclear endpoint
chosen part approv plan util novel diseas grade scale
evalu liver histolog trial also unclear whether fda agre
improv composit endpoint clinic meaning threshold number
patient would need approv dataset serum level predict
develop sever lung liver diseas individu patient basi fregones et
al orphanet limit use surrog biomark clinic
activ part sequoia current enrol patient part studi
expect initi
aro-aat lead pack competit rnai landscap though could
disrupt entrant alni phase develop plan dose
first patient phase trial unclear whether differenti exist
rnai agent see vrtx small molecul corrector program largest threat
aro-aat rnai approach rnai therapi potenti exacerb lung
diseas deplet protein serum vrtx corrector could increas
protein function serum protect lung diseas also reduc
format accumul misfold protein drive aatd liver diseas potenti
provid safeti efficaci advantag addit conveni oral administr see
note colleagu geoffrey porg
financi project peak sale given competit environ
aatd liver diseas model peak penetr aro-aat segment
aatd popul believ would make good candid treatment approv
disease-modifi therapi would like lead increas physician awar model
higher diagnosi rate aatd liver diseas time though benefit larger patient
pool share compet rnai agent vrtx small molecul corrector
aro-aat revenu model us popul incid pizz incid liver diseas pizz penetr treat aro-aat- prob-weight patient per patient treat per defici sale mm defici mm europetot eu popul incid pizz incid liver diseas pizz penetr treat aro-aat- prob-weight patient annual cost per patient defici european revenues- defici european revenues- defici row royalti mm defici row defici ww revenues- defici revenues- sourc svb leerink estimateskey assumptionsaro-aat incid liver complic in pizz cost price increas eu price increas sale arrowhead inc
target apolipoprotein c-iii apoc-iii reduc plasma triglycerid
apoc-iii key compon triglyceride-rich lipoprotein plasma deplet
apoc-iii lower serum triglycerid includ low densiti lipoprotein vldl
chylomicron initi phase data demonstr mean maxim knockdown
apolipoprotein c-iii protein singl dose maxim triglycerid
reduct exhibit accompani reduct triglycerid
vldl cholesterol exhibit long-term benefit lower apoc-iii express
support larg genet associ studi demonstr individu carrier
loss function mutat lower mean circul apoc-iii
correspond lower plasma triglycerid level lower risk coronari heart
diseas compar noncarri toth vasc health risk manag
exhibit singl dose volunt knockdown
launch price probabl success arrowhead inc
exhibit singl dose hv chang triglycerid vldl
elev triglycerid substanti increas risk cardiovascular diseas
hypertriglyceridemia defin sustain fast triglycerid mg/dl
associ increas risk death myocardi infarct exhibit
us adult thought hypertriglyceridemia includ estim million
adult age treat statin et al jour clin lipidolog
statin-tr adult high triglycerid associ increas risk
atherosclerot cardiovascular diseas ascvd suggest decreas
triglycerid could lower risk patient
exhibit elev triglycerid associ w/ increas risk ischem event
exhibit ascvd risk increas individu hypertriglyceridemia
fan et al journal clinic lipidolog
plan first pursu famili chylomicronemia syndrom fc
fc ultra-rar patient world-wide hereditari diseas character
sever hypertriglyceridemia accumul lipoprotein particl major patient
harbor homozyg inactiv mutat lipoprotein lipas lpl gene caus
plasma triglycerid normal level significantli increas risk
morbid mortal recurr pancreat target apoc-iii protein rnai
upregul lpl-independ catabol pathway lead reduct total plasma
exhibit role fc
data ions/akca program valid triglyceride-low
target phase approach studi waylivra demonstr sustain
reduct mean apolipoprotein c-iii level baselin correl drop
triglycerid witztum et al nejm waylivra deplet
substanti triglycerid reduct approach valid target
waylivra receiv complet respons letter us due off-target safeti
concern receiv posit chmp opinion ema approv base drug
effect reduc triglycerid fc patient
though still quit earli data single-dos portion aro-
phase studi present aha scientif session robust
knockdown reduct triglycerid cholesterol cholesterol
demonstr prematur discontinu seriou
healthi volunt dose earlier data cut global summit
cardiolog heart diseas healthi volunt demonstr mean maxim
protein knockdown maxim triglycerid reduct similar
phase data akcea-apociii-lrx exhibit enrol single-dos portion
studi complet multiple-dos portion studi enrol healthi
volunt patient sever hypertriglyceridemia famili chylomicronemia
syndrom fc anticip initi pivot phase studi
orphan diseas indic
exhibit mean maxim reduct triglycerid baselin
given bd global summit cardiolog heart diseas
nv exercis option develop akcea-apociii-lrx suggest
may attract target treat hypertriglyceridemia decemb
nv chose exercis option develop akcea-apociii-lrx strateg
portfolio decis compani arriv decis prior anticip releas top-
line phase ii data dont believ neg reflect qualiti
ackea-apociii-lrx phase ii data may indic apociii knockdown agent could
limit orphan diseas view favor treatment gener
hypertriglyceridemia knockdown discuss
achiev monoclon antibodi aso ions/pf rnai
demonstr abil achiev signific reduct triglycerid
also significantli reduc ldl-c exhibit addit label vascepa
recent expand includ patient greater mg/dl cardiovascular
diseas diabet least two risk factor heart diseas maxim statin use
fairli broad indic larg total address market vascepa remain
controversi among investor estim uptak patient triglycerid tg
level mg/dl vari wide vascepa would directli compet aro-
mass market triglyceride-low indic open possibl
payor could requir step vascepa arwr much expens follow-on
triglyceride-low therapi see work colleagu ami fadia
though sever orphan popul combin therapi possibl well
financi model two market segment orphan diseas fcs/fpl
patient recurr pancreat due hypertriglyceridemia two small indic
would abl pursu independ without larg pharma partner partnership
develop larger indic could gener up-front payment
long-term royalti current unmodel could lead upsid
estim though compani activ seek partnership
also note approv akcea-apociii-lrx primari secondari indic
would like limit price opportun scenario believ patient
fcs/fpl recurr pancreat would like fall presum akcea-
apociii- lrx label due elev triglycerid price power would
limit drastic reduc revenu orphan indic
headwind must balanc upsid potenti up-front payment
revenu build us treat annual price total gross fc sale mm risk adjust fc sale mm fc eu treat annual price total gross fc sale mm risk adjust fc sale mm fpl us treat annual price total gross fpl sale mm total risk-adjust fpl sale mm fpl eu treat annual price total gross fpl sale mm total risk-adjust fpl sale mm total gross sale mm total risk-adjust sale mm arrowhead inc
exhibit sensit analysi fcs/fp recurr pancreat
revenu build recurr statestot us popul adult pt recurrent/chron pancreatit adult pt recurrent/chron pancreatit due treat per cours total gross sale risk-adjust sale row total eu sale risk-adjust sale row sale risk-adjust sale row royalti ww sale recurr pancreat risk-adjust sale ww sale risk-adjust ww sale annual orphan annual recurr price growth recurr revenu revenu launch price fcs/fpl probabl launch price recurr pancreat probabl success arrowhead inc
inhibit express key regul lipoprotein
metabol angiopoietin-lik protein secret inhibitor lipoprotein
lipas endotheli lipas produc primarili liver exhibit loss
express protect cardiovascular diseas cvd larg genome-wid
associ studi associ loss-of-funct allel low level
total cholesterol cholesterol triglycerid individu loss-of-funct
mutat also found risk reduct coronari arteri
diseas compar individu normal allel stitziel et al
cardiol evid also suggest inactiv associ
increas insulin sensit robciuc mr et al lipid preclin clinic
data demonstr inhibit activ significantli lower serum triglycerid
ldl-c hdl-c may wide rang applic treat dyslipidemia
exhibit interact lipoprotein lipas endotheli lipas
plan initi develop homozyg famili
hypercholesterolemia hofh orphan indic signific unmet need
homozyg famili hypercholesterolemia hofh rare metabol diseas affect
peopl us character early-onset cvd high
level hofh recess disord caus inherit mutat receptor gene
ldlr patient present ldl-c level normal lead early-onset
cardiovascular diseas death second third decad life left untreat
exercis statin first line therapi though vast major patient
suffici control statin alon addit medic sequenti
ad inhibitor first medic ad top statin follow
addit ezetimib lomitapid juxtapid final period apheresi given
sub-optimal respons multipl line medic toler issu associ
concomit treatment remain high degre unmet need potent ldl-c
reduc therapi hofh
potenti wide rang dyslipidemia though develop path
beyond hofh remain unclear initi phase data healthi volunt demonstr
sustain reduct express triglycerid singl dose aro-
singl dose escal studi evalu dose
adult healthi volunt singl dose lower serum
mean maximum plasma triglycerid mean maximum
exhibit dose select multipl dose portion
studi enrol patient variou dyslipidemia includ patient elev
cholesterol stabl statin hypertriglyceridemia non-alcohol steatohepat
nash hefh hofh
exhibit knockdown adult volunt knockdown
exhibit knockdown hv chang triglycerid vldl
exhibit knockdown compar evinacumab
given bd global summit cardiolog heart diseas inclus criteria tg
mg/dl dose-depend increas indic target bind observ
reduct activ significantli reduc cholesterol hofh patient
inhibit valid clinic trial evinacumab anti-
antibodi develop op random placebo-control phase
trial hofh patient treat evinacumab demonstr decreas
cholesterol baselin compar increas baselin placebo mg/dl
reduct compar mg/dl placebo reduct evinacumab-tr patient
achiev cholesterol level mg/dl compar placebo patient
antibodi mechan action differ mrna deplet import way
inhibit activ rnai expect similar effect
cholesterol expect submit bla approv first-to-market advantag
similar mab fast-follow rnai agent inclisiran mdco
watch develop market determin conveni benefit rnai
dose valu commerci set entrench mab competit
pfizer-ions/akca partnership offer potenti comp asset
announc licens agreement includ sizabl
up-front payment potenti develop regulatori sale mileston
tier double-digit royalti world-wide sale licens prior
complet phase ii studi suggest phase ii data arent
necessari licens larg pharma appetit
compound could support up-front payment though lag
develop may conveni advantag
pk/pd support dose interv month
like enter pivot studi once-per-month dose
regimen could moder ions/pf first-mov advantag assum trim
platform continu show safeti burden would chang clinic risk/reward
calculu howev arwr day octob compani emphas
current look out-licens asset pipelin believ
lower chanc larg pharmaceut partnership immin
model treatment hypercholesterolemia proxi primari
secondari prevent given substanti price paid believ
like develop mass market indic similar inclisiran
strategi pursu mdco nv hypercholesterolemia
manag state activ seek out-licens drug exist
pipelin premium share assum robust franchis common
cardiometabol diseas reflect option share despit manag
protest contrari model partnership treatment
hypercholesterolemia sinc littl clariti market could
develop assum develop hypercholesterolemia similar inclisiran
reason approxim phase develop suggest earliest
could reach market cardiovascular outcom studi given
cost associ assum partner phase develop collect royalti
offload bulk cost larg pharmaceut partner list price
could reach sale translat approxim
royalti assum probabl success
hypercholesterolemia program though note scenario play orphan
opportun asset would fall near zero due loss orphan price hofh/hefh
financi model approv first hofh follow hefh larg
pharmaceut partnership larg hypercholesterolemia indic hofh orphan
diseas high unmet need believ could support cost
hofh also model uptak hefh patient control
cholesterol statin exhibit note market like support price
par therapi preval cardiometabol diseas compet
asset etc approv larg indic
treatment option lower priced/high-efficaci competit would substanti decreas
opportun hofh list price praluent fallen
institut clinic econom review icer report value-bas
benchmark rang patient ldl-c mg/dl
maxim toler statin higher-risk patient
sustain ldl-c level greater statin therapi icer
formal influenc price report low list price praluent suggest
current payer environ support list price much ascrib
probabl success hofh hefh program peak sale impli
probability-weight peak sale establish partner develop ang-
larger indic up-front payment long-term royalti would lead upsid
estim though could also collaps realiz price hofh hefh
commensur model valu orphan mass-market indic
recogn ultim like deriv valu one strategi
due price inconsist
hofh launch price probabl success hofh hefh arrowhead inc
homozyg famili hypercholesterolemia revenu us popul patient hofh patient untreat gene patient adequ treat soc elig patient treat elig patient treat patient treat price per treatement sale mm yoy growth sale total eu popul eu patient hofh patient previous untreat gene patient adequ treat soc elig patient treat elig patient treat patient treat price per treatement eu sale mm yoy growth eu sale rest world patient treat probabilty-adjust patient treat row sale mm yoy growth row sale mm ww hofh sale mm probability-adjust ww hofh sale mm arrowhead inc
exhibit revenu build hefh
heterozyg famili statestot us popul patient patient w/ldl-c inadequ treat treat per year total sale risk-adjust sale row total eu popul eu patient patient w/ldl-c eu inadequ treat treat per year total eu sale risk-adjust eu sale row sale row royalti row royalti ww hefh sale risk-adjust hefh sale assumptionshofhu popul growth live birth per adaqu treat soc cost price growth popul growth price growth launch price vs us launch price patient treat vs price growth /year revenu revenu arrowhead inc
exhibit revenu build hypercholesterolemia
elev lipoprotein common independ risk factor cardiovascular
diseas lp thought elev approxim us adult though lp
consid major risk factor cardiovascular diseas decad
regularli screen lipid panel niacin vitamin shown reduc lp
random clinic trial inhibitor praulent demonstr
reduct lp approv dose stein ea et al cardiovascular drug
therapi patient lp far mg/dl threshold could use
addit option decreas cardiovascular risk associ elev lp
revenu hypercholesterolemia treat lipid lower treat lipid-low yr-old lipid lower average annual statin achiev ldl-c treat treat statin intoler candid treat treat total treat total untreat us market penetr patients- sale sale sale sale royalti royalti pos-adj sale pos-adj sale pos-adj sale royalti pos-adj royalti arrowhead inc
aro-lpa target apolipoprotein major compon lp
formerli aro-lpa design inhibit product apolipoprotein prevent
cardiovascular diseas phase trial current enrol patient
elev lp phase trial expect present initi clinic data
cohort either plan begin phase ii studi
would trigger mileston payment
larg hypothet potenti lp -lower agent though larg undevelop
market convers medacorp kol suggest larg potenti market
lp reduc agent though approv reimburs requir demonstr
cardiovascular outcom benefit medacorp kol suggest reduct
cardiovascular risk would approv fda reduct cardiovascular
risk would clear win lp lower agent whether benefit would
demonstr top agent clinic trial design requir support
commerci viabl label remain unclear addit would market-build
activ despit rel high frequenc lp elev lp current
includ lipid panel typic screen individu famili histori
elev lp earli onset cardiovascular diseas recurr cardiovascular diseas
resist statin introduc lp screen panel would help identifi individu
high lp level despit otherwis normal metabol screen would involv
great deal heavi lift demand robust clinic data support
financi project peak ww sale given potenti broad
applic apolipoprotein apo -reduc therapi apo market analog
market believ apo price like range-bound similar
manner monoclon antibodi praluent launch initi list price
though price reduc due payer
pushback launch demonstr lipid-low therapi market
sensit price even face strong cardiovascular outcom data icer evid
report set value-bas benchmark patient
ldl-c mg/dl maxim toler statin
higher-risk patient sustain ldl-c level greater
statin therapi icer formal influenc price
low value-bas assess antibodi despit strong cardiovascular outcom
data price concess suggest price could similarli limit given
lack target apo therapi patient risk gener model market
support increment higher list price apo -lower agent year
statesadult pt lp plasma level patient establish cardiovascular pt establish cvd high patient inadequ treat pt inadequ treat treat per year total sale risk-adjust sale royalti row total eu sale risk-adjust sale eu royalti row sale risk-adjust sale row royalti ww sale risk-adjust sale row royalti price growth /year revenu revenu launch price probabl success arrowhead inc
chronic hbv infect signific unmet need function cure chronic hbv
affect million peopl world-wide highest rate infect asian-pacif
region liaw yf hepatol current treatment option low rate function
cure defin sustain undetect hepat surfac antigen hbsag hbv dna
serum standard-of-car interferon nucleo ide analogu nuc treatment suppress
viral replic prevent liver damag associ hbv infect drug
must taken chronic avoid viral rebound background hbv emerg
competit landscap extens review colleagu op
initi see also publish competit posit dcr-hbv
context hbv-target oligo therapi see note
exhibit hbv life cycl avenu therapeut intervent
function hbv cure like requir cpam nuc rna deplet nuc
oral administ well-toler display potent activ manag chronic hbv
patient risk viral reactiv nuc treatment ceas even patient
achiev hbsag seroclear defin two consecut neg hbsag test
perform least six month apart fung et al journal antimicrobi chemotherapi
decemb one promis approach could potenti achiev
function hbv cure addit core protein alloster modifi cpam rna
deplet w/ rnai aso nuc therapi aro-hbv rnai cocktail includ
two distinct molecul silenc rna transcript associ hbv exhibit
advanc compon potenti cur hbv combin therapi
capsid modul nucleo ide analogu
exhibit util two rnai molecul silenc hbv transcript
initi clinic data demonstr robust knockdown hbsag e-antigen neg
posit patient interim analysi present aasld
demonstr mean log peak reduct hbsag e-antigen neg patient
mean log peak reduct hbsag e-posit patient patient
day follow-up gane et al aasld exhibit
on-going debat degre hbsag antigen reduct need function cure
medacorp kol consid log reduct suffici incorpor
combin therapi bar clearli achiev higher dose
phase i/ii studi expand includ tripl combin cohort
includ capsid assembl modul nuc initi combo data
first patient dose present aasld time-frame
day tripl combo appear similar nuc e-neg patient
demonstr log peak reduct hbsag e-posit patient demonstr
mean peak log reduct janssen initi phase iib studi
evalu combin regimen includ and/or jnj-
and/or nuc week chronic hbv patient
exhibit mean hbsag reduct baselin
multipl rnai compani jockey posit cur hbv regimen
first asset test clinic rnai backbon tripl combin therapi
hbv believ first-to-market signific advantag hbv treatment given
cur therapi deplet patient pool time despit advantag
sever compet agent develop op nr
arbutu abu nr compet rnai oligonucleotid partner gsk
op develop aso-bas hbv therapi date program gener
clinic data e-antigen neg patient receiv mg display
log reduct hbsag patient administ dose demonstr
mean reduct log exhibit partner gsk present date hbv
program aasld treatment reduc hbsag log
overal treatment popul highest dose mg weekli arbutu rnai
compound demonstr robust knockdown hbsag though compani recent
discontinu develop lead capsid inhibitor futur uncertain
exhibit develop landscap rnai hbv
financi project see larg market function hbv cure could support
peak sale assum royalti rate revenu
would translat peak royalti exhibit price power hbv
treatment highest eu geographi though largest revenu opportun
china could approv us eu earli believ
chines approv could come time-frame phase data
promis howev assign probabl success program
due uncertainti regard possibl function cure rnai oligo nuc
cpam
companydrug namepreclin reduct hbsag levelspreclin reduct hbsag level singl dose clinic reduct hbsag levelsclin statusalnylam/vir log log reduct cohort cohort logphas log log reduct daysn/aphas log log reduct daysreduct log e-antigen neg reduct log e-antigen posit phase log reduct least week n/aphas patient sale mm us saleseu saleschina salesjapan sale patient treat arrowhead inc
christoph anzalon presid ceo
dr christoph anzalon presid ceo director arrowhead
pharmaceut sinc decemb prior join arrowhead dr anzalon form
serv ceo benet group llc partner washington dc-base
privat equiti firm galway partner llc dr anzalon hold ph biolog ucla
 govern lawrenc univers nih-support post-
doctor fellow reproduct endocrinolog smithsonian institut conserv
research center
dr bruce given join arrowhead chief oper offic dr given
member board director icon plc chairman
board director dr given serv presid ceo
member board director
sinc octob dr given director inc prior
tenur encys dr given held sever senior execut role johnson
johnson schering-plough dr given obtain bachelor
scienc degre colorado state univers degre univers
chicago pritzker school medicin complet medic train univers
chicago brigham women hospit boston clinic fellow
harvard medic school board certifi intern medicin endocrinolog
kenneth myszkowski join arrowhead previous mr myszkowski serv
corpor control broadwind energi control epcor usa
headquart epcor util inc prior epcor mr myszkowski control
nanoink delphion two start-up ventur mr myszkowski also held sever corpor
role premark intern mr myszkowski receiv
undergradu degre univers illinoi mba univers
chicago booth school busi certifi public account
prior join arrowhead dr san martin serv svp head global clinic
develop ultragenyx sinc led develop burosumab novel
drug treatment x-link hypophosphatemia approv across major region
includ us eu canada serv svp clinic develop alder
biopharmaceut respons manag medic regulatori
clinic oper group focus earli clinic program dr san
martin global develop leader inc respons two
major develop program direct romosozumab clinic program
end phase ii respons develop approv
denosumab largest brand anti-osteoporosi treatment postmenopaus
osteoporosi first monoclon antibodi address preval diseas treat
primari care physician receiv medic degre univers bueno
air medic school complet resid intern medicin cemic univers
hospit bueno air argentina serv chief resid thereaft attend
physician respons intern medicin ward
dr curt bradshaw co-found presid cso member board
director tollnin compani develop novel antibodi conjug immuno-
oncolog prior cso member board director solstic
biolog vice-president cso traversa therapeut primari
oversight key strateg contributor intern technolog develop busi
strategi oversaw research allianc multipl major pharmaceut collabor
dr bradshaw also spent year covx research cornerston inc
bioinnov biotherapeut center member research
develop corpor team provid strateg tactic support research
develop program spent four year
respons chemic develop clinical-phas activ pharmaceut ingredi
dr bradshaw start career spent year
research chemist senior research chemist project leader receiv ph
organ chemistri texa univers
patrick obrien join arrowhead decemb mr obrien practic
healthcar legal field year join compani mr
obrien shire group vice presid law immedi prior
work shire partner intern law firm holland knight llp
washington dc offic mr obrien co-found law firm obrien gould pllc
join holland knight mr obrien partner
burk oneil llc mr obrien serv sever legal role johnson
 johnson includ serv vice presid law js centocor ortho-biotech unit
mr obrien previous serv regulatori counsel unit state food drug
administr mr obrien award bs pharmaci pharmd
univers arizona complet resid clinic pharmaci univers
illinoi chicago hospit also award jd univers arizona
research develop
gener administr expens
sale market
chang valu deriv
total incom expens
loss incom tax
provis incom tax
research develop
 ex sale market
sale market revenu
sec file svb leerink research estim
cash equival
properti equip net
accru payrol benefit
defer revenu net current portion
note payabl net current portion
accumul comprehens incom loss
total liabil stockhold equiti
sec file svb leerink research estim
chang valu deriv
depreci amort
amort accret note premium discount
prepaid expens current asset exclud receiv
princip payment capit leas note payabl
payment tax net share settl restrict stock unit
proce exercis warrant stock option
proce issuanc common stock prefer stock net
net increas decreas cash
begin period
end period
net cash use oper activ
purchas properti equip
purchas market secur
proce sale market secur
net cash use provid invest activ
net cash provid use financ activ
